Hemab Therapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of HMB-003, an Investigational Therapy for the Management of Heavy Menstrual Bleeding
Hemab Therapeutics (Nasdaq: COAG) dosed the first healthy volunteer in a Phase 1 trial of HMB-003, an investigational fatty-acid-conjugated peptide antifibrinolytic purpose-built for heavy menstrual bleeding. The randomized, placebo-controlled, single-ascending-dose study (NCT07798505) will assess safety, tolerability, pharmacokinetics and pharmacodynamics; preclinical work showed a single subcutaneous dose sustained antifibrinolytic activity for about one week in minipigs, supporting potential once-per-cycle dosing versus today's short-acting therapies. Results are expected no later than mid-2027.
Key figures
- Drug Name
- HMB-003
- Phase Of Trial
- Phase 1
- Trial id
- NCT07798505
- Trial design
- randomized, placebo-controlled, single-ascending-dose escalation in healthy adult volunteers
- Us economic cost
- more than $94 billion annually from missed work
- Hmb prevalence us
- approximately 1 in 3 reproductive-aged women; more than 23 million women in the U.S.
- Data update expected
- no later than the middle of 2027
- Preclinical durability
- approximately one week of sustained antifibrinolytic activity from a single subcutaneous dose in minipigs
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.